Analytical and strategy-minded professional with extensive experience in corporate business development transactions, strategy, start-up investments, M&A, and alliance management. Adept at leveraging a blend of business, product, platform technology, and portfolio expertise supporting multi-national biopharmaceutical and life science companies. Skilled in the evaluation of multi-faceted, complex transaction structures, leading the deal lifecycle from strategy development to successful negotiation, building business cases for stakeholder buy-in at the C-suite and board-level, and maintaining strong relationships with third-party partners. A deal sheet that includes both buy- and sell-side licensing (for platform technologies and clinical-stage programs), M&A, non-dilutive financing, limited partner investments, and asset purchase. Recognized for leading collaborative cross-functional teams, engaging stakeholders, and maintaining an accessible network of professionals and information sources, including inventors, academics, trade group leaders, industry peers, consultants, sell-side bankers, venture capital and media contacts. Areas of therapeutic interest and experience include: oncology (i.e. small molecules), immuno-oncology (i.e. antibodies and antibody drug conjugate), cell and gene therapy, genomic engineering, ophthalmology, CNS, neurology, and autoimmune.